WHO Drug Information Vol. 15, No. 2, 2001
(2001; 91 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Ouvrir ce répertoire et afficher son contenuGeneral Information
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentNew Zealand and Australia: joint medicines regulatory body
Afficher le documentBupropion safety information
Afficher le documentBupropion update
Afficher le documentItraconazole and congestive heart failure
Afficher le documentTerbinafine and hepatic failure
Afficher le documentPaediatric amiodarone labelling changes
Afficher le documentCerivastatin: marketing discontinued
Afficher le documentPhenylpropanolamine withdrawn from market
Afficher le documentCounterfeit filgrastim
Afficher le documentOxycodone: strengthened warning
Afficher le documentNesiritide for heart failure
Afficher le documentOprelvekin: paediatric safety information
Afficher le documentPeginterferon alfa-2b combined use: new labelling
Afficher le documentRibavirin for combined use
Afficher le documentSleep attacks with pramipexole and ropinirole
Afficher le documentRosiglitazone-associated hepatic and cardiovascular events
Afficher le documentClarithromycin: labelling change
Afficher le documentHerbal OTC remedy and hepatic dysfunction
Afficher le documentAntipsychotics and high prolactin
Afficher le documentSildenafil: not for use with nitrates
Afficher le documentPropofol, heart failure and high dosages
Afficher le documentBupropion and seizures
Afficher le documentNeurotoxicity with aciclovir and valaciclovir
Afficher le documentRevised labelling for levocarnitine
Afficher le documentAvoid trastuzumab and anthracyclines
Ouvrir ce répertoire et afficher son contenuATC/DDD Classification
Ouvrir ce répertoire et afficher son contenuEssential Drugs
Ouvrir ce répertoire et afficher son contenuRecent Publications and Sources of Information
Afficher le documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
Afficher le documentDénominations communes internationales des Substances pharmaceutiques (DCI)
Afficher le documentDenominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)
Afficher le documentAmendments to previous lists/Modifications apportées aux listes antérieures/Modificaciones a las listas anteriores
Afficher le documentAnnexes
 

Neurotoxicity with aciclovir and valaciclovir

Sweden - Reports of central nervous system disorders, including confusion, hallucinations, psychosis, agitation, seizures, and impaired coordination, have been made to the Swedish adverse drug reactions data base at the Medicines Products Agency.

Many of the affected patients had renal insufficiency and most were aged over 60 years of age. Approximately half the patients with renal insufficiency who experienced CNS effects received higher than recommended dosages of the drugs; the product information states that the dosage should be adjusted to a patient’s degree of renal insufficiency. Concomitant psychoactive medications could also be a risk factor. Such adverse reactions can be treated with haemodialysis, which results in symptomatic improvement.

Reference: Medicines Products Agency, 12: 30, February 2001.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013